INT132523

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.29
First Reported 2006
Last Reported 2006
Negated 0
Speculated 1
Reported most in Abstract
Documents 2
Total Number 3
Disease Relevance 1.29
Pain Relevance 0.18

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (RASGRP1) Golgi apparatus (RASGRP1) endoplasmic reticulum (RASGRP1)
cytoplasm (RASGRP1) cytosol (RASGRP1) lipid binding (RASGRP1)
RASGRP1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 2 91.16 High High
palliative 3 45.44 Quite Low
Pain 1 14.60 Low Low
dexamethasone 2 5.00 Very Low Very Low Very Low
Spinal cord 1 5.00 Very Low Very Low Very Low
Analgesic 1 5.00 Very Low Very Low Very Low
Intractable pain 1 5.00 Very Low Very Low Very Low
addiction 1 5.00 Very Low Very Low Very Low
Kinase C 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cancer 14 99.44 Very High Very High Very High
Ovarian Cancer 8 99.32 Very High Very High Very High
Adhesions 3 92.36 High High
Apoptosis 8 71.36 Quite High
Metastasis 11 56.80 Quite High
Breast Cancer 25 50.00 Quite Low
Lung Cancer 2 31.72 Quite Low
Pain 1 14.60 Low Low
Hypercalcemia 3 5.00 Very Low Very Low Very Low
Multiple Myeloma 3 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Since elevated activation of the RAS signaling pathway, including overexpression of HER-2/neu and mutations of RAS and BRAF, is common in human ovarian carcinoma, we examined the cellular effect of oncogenic RAS on the expression status of OPCML in a genetically defined human ovarian cancer model.
Spec (examined) Positive_regulation (activation) of Gene_expression (overexpression) of RAS associated with ovarian cancer
1) Confidence 0.29 Published 2006 Journal FASEB J. Section Abstract Doc Link 16384911 Disease Relevance 0.48 Pain Relevance 0.09
Since elevated activation of the RAS signaling pathway, including overexpression of HER-2/neu and mutations of RAS and BRAF, is common in human ovarian carcinoma, we examined the cellular effect of oncogenic RAS on the expression status of OPCML in a genetically defined human ovarian cancer model.
Positive_regulation (overexpression) of Gene_expression (overexpression) of RAS associated with ovarian cancer
2) Confidence 0.29 Published 2006 Journal FASEB J. Section Abstract Doc Link 16384911 Disease Relevance 0.47 Pain Relevance 0.09
Conversely, inhibition of Ras activation resulted in radiosensitization both in rodent cells transfected with Ras and in human tumor cells bearing endogenous mutations in Ras [26].
Positive_regulation (transfected) of Gene_expression (transfected) of Ras associated with cancer
3) Confidence 0.12 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779467 Disease Relevance 0.34 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox